SCHEMBL6483799

SCHEMBL6483799

O=S(=O)(Nc1cccc(CCOCc2ccc(Br)cc2F)c1)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.39
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
CYSLTR2 Q9NS75 1/20 0.37
CYSLTR1 Q9Y271 1/20 0.37
HTR6 P50406 2/20 0.35
CA1 P00915 1/20 0.35
KDM1A O60341 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
PTPN1 P18031 1/20 0.33
PFKFB4 Q16877 1/20 0.32
NPC1 O15118 1/20 0.32
PDPK1 O15530 1/20 0.32
PRMT6 Q96LA8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481112 0.86 KDM1A (0.41) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6482230 0.84 KIF11 (0.44) CA2CYSLTR2CYSLTR1KDM1A
SCHEMBL6474641 0.83 NAAA (0.40) CA2KDM1APRMT6
SCHEMBL6474335 0.83 KDM1A (0.39) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6481745 0.82 EPHX2 (0.41) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6482513 0.82 CNR1 (0.39) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6482076 0.82 KDM1A (0.38) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6474136 0.82 NAAA (0.40) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6474838 0.80 SHMT1 (0.37) CA2PTGS1PTGS2CYSLTR2CYSLTR1
SCHEMBL6479679 0.78 KDM1A (0.42) CA2PTGS1PTGS2CYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 CA2 2137/4885PTGS1 1260/4885PTGS2 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.